Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?

 
• By Mandy Jackson
  
Risk versus value matrix with pushpins and blur effect. Concept of investment risk assessment.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business